356
Participants
Start Date
December 22, 2021
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2027
Orelabrutinib and R-CHOP
Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
R-CHOP
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
NOT_YET_RECRUITING
The Fourth Hospital of Hebei Medical University, Shijiazhuang
RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
The First Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
The First Hospital of Jilin University, Changchun
NOT_YET_RECRUITING
Jiangsu Province Hospital, Nanjing
NOT_YET_RECRUITING
The First Affiliated Hospital of Soochow University, Suzhou
NOT_YET_RECRUITING
Anhui Province Cancer Hospital, Hefei
NOT_YET_RECRUITING
Shandong Provincial Hospital, Jinan
NOT_YET_RECRUITING
Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin
NOT_YET_RECRUITING
Tianjin Cancer Hospital, Tianjin
NOT_YET_RECRUITING
he First Affiliated Hospital of Zhengjiang University, Hangzhou
NOT_YET_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
NOT_YET_RECRUITING
Tumor in Hunan Province, Hunan
NOT_YET_RECRUITING
Wuhan Union Hospital, Wuhan
NOT_YET_RECRUITING
Henan Tumor Hospital, Zhengzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Guangzhou First People's Hospital, Guangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Guangxi Medical University, Guangxi
NOT_YET_RECRUITING
West China Hospital,Sichuan University, Chengdu
NOT_YET_RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
Beijing InnoCare Pharma Tech Co., Ltd.
INDUSTRY